KR101835739B1 - Composition comprising extracts or fractions of Artemisia capillaris as an effective ingredient - Google Patents
Composition comprising extracts or fractions of Artemisia capillaris as an effective ingredient Download PDFInfo
- Publication number
- KR101835739B1 KR101835739B1 KR1020150086839A KR20150086839A KR101835739B1 KR 101835739 B1 KR101835739 B1 KR 101835739B1 KR 1020150086839 A KR1020150086839 A KR 1020150086839A KR 20150086839 A KR20150086839 A KR 20150086839A KR 101835739 B1 KR101835739 B1 KR 101835739B1
- Authority
- KR
- South Korea
- Prior art keywords
- ethyl acetate
- extract
- fraction
- concentration
- solvent
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 106
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- 241000092668 Artemisia capillaris Species 0.000 title claims abstract description 20
- 235000008658 Artemisia capillaris Nutrition 0.000 title claims abstract description 20
- 239000004615 ingredient Substances 0.000 title description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 230000002087 whitening effect Effects 0.000 claims abstract description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000004480 active ingredient Substances 0.000 claims abstract description 23
- 238000004519 manufacturing process Methods 0.000 claims abstract description 17
- 239000012046 mixed solvent Substances 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 138
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 87
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 87
- 229940093499 ethyl acetate Drugs 0.000 claims description 46
- 235000019439 ethyl acetate Nutrition 0.000 claims description 46
- 239000002904 solvent Substances 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 239000011259 mixed solution Substances 0.000 claims description 23
- 235000007823 Artemisia sp Nutrition 0.000 claims description 21
- 244000298939 Artemisia sp Species 0.000 claims description 21
- 239000002032 methanolic fraction Substances 0.000 claims description 18
- 239000002038 ethyl acetate fraction Substances 0.000 claims description 17
- -1 octadecylsilyl silica gel Chemical compound 0.000 claims description 13
- 239000000741 silica gel Substances 0.000 claims description 6
- 229910002027 silica gel Inorganic materials 0.000 claims description 6
- 229960001866 silicon dioxide Drugs 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 239000011877 solvent mixture Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 abstract description 40
- 210000003491 skin Anatomy 0.000 abstract description 32
- 235000017519 Artemisia princeps Nutrition 0.000 abstract description 31
- 244000065027 Artemisia princeps Species 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 26
- 230000003078 antioxidant effect Effects 0.000 abstract description 20
- 230000002401 inhibitory effect Effects 0.000 abstract description 20
- 238000002360 preparation method Methods 0.000 abstract description 19
- 206010061218 Inflammation Diseases 0.000 abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 13
- 239000003963 antioxidant agent Substances 0.000 abstract description 13
- 201000001441 melanoma Diseases 0.000 abstract description 11
- 239000000344 soap Substances 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 210000002752 melanocyte Anatomy 0.000 abstract description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 46
- 238000009472 formulation Methods 0.000 description 21
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 240000006891 Artemisia vulgaris Species 0.000 description 14
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- 102000003425 Tyrosinase Human genes 0.000 description 12
- 108060008724 Tyrosinase Proteins 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- 235000006708 antioxidants Nutrition 0.000 description 11
- 239000006210 lotion Substances 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 230000004054 inflammatory process Effects 0.000 description 10
- 239000003960 organic solvent Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 230000008099 melanin synthesis Effects 0.000 description 9
- 235000003826 Artemisia Nutrition 0.000 description 8
- 241000271889 Artemisia japonica Species 0.000 description 8
- 235000017521 Artemisia japonica Nutrition 0.000 description 8
- 235000009052 artemisia Nutrition 0.000 description 8
- 230000003834 intracellular effect Effects 0.000 description 8
- 239000012223 aqueous fraction Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003205 fragrance Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 6
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 description 6
- 230000032683 aging Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 239000000469 ethanolic extract Substances 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000002044 hexane fraction Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000003061 melanogenesis Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 235000013402 health food Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 206010003645 Atopy Diseases 0.000 description 3
- 229920002498 Beta-glucan Polymers 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 229920001214 Polysorbate 60 Polymers 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 230000007760 free radical scavenging Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 235000019482 Palm oil Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 244000061458 Solanum melongena Species 0.000 description 2
- 235000002597 Solanum melongena Nutrition 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- RAZOKRUZEQERLH-UHFFFAOYSA-N capillin Chemical compound CC#CC#CC(=O)C1=CC=CC=C1 RAZOKRUZEQERLH-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002540 palm oil Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- WMYLYYNMCFINGV-CKCBUVOCSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O WMYLYYNMCFINGV-CKCBUVOCSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000238582 Artemia Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 240000002045 Guettarda speciosa Species 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 206010027145 Melanocytic naevus Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000009262 Puerariae Radix plant extract Substances 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 238000000944 Soxhlet extraction Methods 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241001180927 Trigonotis peduncularis Species 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000003450 decanoic acid ester group Chemical group 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000000260 hypercholesteremic effect Effects 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 1
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 1
- 229960004705 kojic acid Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 229960002446 octanoic acid Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 description 1
- 238000009991 scouring Methods 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 208000031019 skin pigmentation disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009861 stroke prevention Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Cosmetics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Abstract
The present invention relates to a composition having anti-inflammatory, antioxidant, skin whitening activity, and anti-inflammatory, antioxidative, skin whitening activity enhancing activity, or a method for producing the fractions thereof, which comprises an extract of Artemisia princeps or a fraction thereof as an active ingredient.
Specifically, extracts of Artemisia capillaris or fractions thereof, which are extracted with water, alcohol or a mixed solvent thereof, are excellent in anti-inflammation, antioxidant and skin whitening activity, and particularly in melanoma cells, melanocytes, Production inhibitory effect, and showed very high activity even in a small amount.
Therefore, the composition containing the extract of Artemisia princeps of the present invention or a fraction thereof as an active ingredient can be usefully applied to cosmetic preparations, soaps, medicines or food compositions.
Description
The present invention relates to a composition having anti-inflammatory, antioxidant, skin whitening activity, and anti-inflammatory, antioxidative, skin whitening activity enhancing activity, or a method for producing the fraction thereof, which comprises Artemisia capillaris extract or a fraction thereof as an active ingredient will be.
In human skin, various physical and chemical changes occur during the aging process. The cause is largely classified into intrinsic aging and photo-aging, and research has been conducted actively. Specifically, free radicals may be activated by ultraviolet rays, stress, disease states, environmental factors, wounds, and aging. If such conditions are deepened, the antioxidant defense network existing in the living body may be destroyed, Thereby promoting adult diseases and aging.
Therefore, it is necessary to protect the cell membrane by destroying the free radicals mediated by free radicals, ultraviolet rays, and inflammation that occur during the metabolism of the body and to proliferate cells by regenerating already damaged cells by active metabolism The skin can be maintained.
On the other hand, melanin is oxidized by tyrosinase to tyrosine (DOPA, 3,4-dihydro xyphenylalanine), converted to dopaquinone by redox oxidation, and then converted to non-enzymatic oxidation Reaction. Melanin protects the skin organs below the dermis by blocking ultraviolet rays, and at the same time, it plays a useful role in protecting the damage of proteins and genes in skin caused by free radicals generated in the skin of the skin. However, when melanin is produced more than necessary, It causes aging and causes hyperpigmentation such as spots or freckles. Melanin has the ability to remove reactive oxygen species, but sometimes melanin itself generates free radicals. It also reduces or oxidizes other substances by catechol or quinone in the melanin structure, and melanin itself has the property of free radicals do. Therefore, inhibition of melanin production may result in a skin whitening effect.
(P-methoxyphenol), hydroquinone, kojic acid, albutin, vitamin C (ascorbic acid), glutathione (glutathione) and the like, which have a skin whitening effect by inhibiting melanin production. glutathione and cystein and plant extracts such as extracts of cucumber herb extract, licorice extract, peony extract, cinnamon extract, gossam extract, Puerariae Radix extract, Angelica gigantosa extract, Problems such as insufficient whitening effect, safety to skin, stability in formulations when added to cosmetics, and the like are still problems to be solved.
Artemisia is a perennial herbaceous plant of Compositae which is distributed in Korea and Asia and Europe. It is known that there are about 400 species. About 300 species are native to Korea, 10-0401472 (Functional beverage containing Artemisia sp. Extract and method for producing the same) describes Artemisia sp. Extract for use in blood vessel relaxation, stroke prevention, or anticancer beverage.
A method for obtaining fractions using solvent polarity for natural products such as mugwort is to sequentially treat hexane, chloroform, dichloromethane, ethyl acetate, and butanol to fractionate the fractions according to the polarity. However, this method has an advantage of being capable of subdividing the substance according to the polarity, but in the experiment for separating the active ingredient, the active ingredient is dispersed.
Accordingly, the inventors of the present invention have devised a method of preventing the dispersion of the active ingredient and obtaining a larger amount of active fraction as compared with the known solvent fractionation method, And to develop a method for producing the extract of Artemisia princeps or its fractions which can best exhibit whitening activity.
It is an object of the present invention to provide a cosmetic composition, a soap composition, a pharmaceutical composition and a cosmetic composition which are effective for anti-inflammation, antioxidant or skin whitening while harmless to the human body by preparing the extract of Artemisia capillaris and its fractions which can best exhibit anti- To provide a food composition.
In addition, the object of the present invention is to provide a method for producing an Artemisia sp. Extract comprising extracting dried matter of Artemisia princeps with water or ethanol / methanol, or extracting and fractionating Artemisia sp. .
In order to achieve the above object, the present invention provides a composition having anti-inflammatory, antioxidant or skin whitening activity, comprising an extract of Artemisia princeps or a fraction thereof as an active ingredient.
The extract of Artemisia capillaris is characterized by being extracted with water, C 1 -C 2 alcohol or a mixed solvent thereof.
Wherein the extract is obtained by extracting an extract of Artemisia japonica with a solvent selected from water, methanol, ethanol or a mixed solvent thereof, and then extracting it again with a mixed solvent of water and ethyl acetate as a solvent.
The above-mentioned fraction of Artemisia princeps is obtained by extracting the extract of Artemisia capillaris with ethyl acetate and further extracting the ethyl acetate fraction with a mixed solvent of methanol and hexane as a solvent.
Wherein the methanol extract is extracted with ethyl acetate and the ethyl acetate fraction is further extracted with a solvent mixture of methanol and hexane to obtain a methanol fraction and the methanol fraction is separated by using a mixed solution of ethyl acetate and hexane .
The mugwort extract or its fractions are characterized by inhibiting NO production, eliminating free radicals, and inhibiting tyrosinase activity and melanin production.
The composition is characterized by being a cosmetic composition, a soap composition, a pharmaceutical composition or a food composition.
The cosmetic composition is characterized by being made of a skin, lotion, cream, essence, gel, pack, cleansing foam, cleansing lotion, cleansing cream, body cream, body lotion, body cleanser, milky lotion, powder or eye shadow formulation.
The composition is characterized by being a pharmaceutical composition for preventing or treating acne, atopy, psoriasis, dermatitis, skin aging, wrinkles or skin hyperpigmentation diseases.
The skin hypercholesterolemic disease is characterized by pigmentation by spots, freckles, blotch, nevus, melanoma, drug, or inflammation.
The present invention also provides a method for preparing a dried eggplant wormy; And
And extracting the dried material with water, a C 1 to C 2 alcohol or a mixed solvent thereof.
In addition, the present invention provides a method of making an Artemisia sp. Fraction comprising the steps of:
(1) preparing a dried mugwort artificially;
(2) extracting the dried material with water, a C 1 to C 2 alcohol, or a mixed solvent thereof; And
(3) Extracting the extract obtained in the step (2) with a mixed solution of ethyl acetate and water as a solvent.
The step of extracting the extract obtained in the step (3) with a mixed solvent of methanol and hexane as a solvent, or a step of extracting a mixed solution of methanol and hexane with a solvent, and then adding the obtained extract to a mixed solution of ethyl acetate and hexane And separating the reaction mixture into a solvent.
According to the present invention, it is possible to provide a cosmetic composition having excellent antiinflammatory, antioxidant and skin whitening effects by providing an extract of Artemisia syrup extract having anti-inflammatory, antioxidant and skin whitening activity and anti-inflammation, antioxidant and skin whitening activity, , A soap composition, a pharmaceutical composition and a food composition.
In addition, the composition containing the extract of Artemisia japonica extract according to the present invention as an active ingredient has an effect of preventing or improving acne, atopy, psoriasis, dermatitis, skin aging, wrinkles or skin hyperpigmentation diseases while being safe for skin.
Also, according to the present invention, it is possible to develop a cosmetic composition or a soap composition having an excellent skin whitening effect by providing a composition containing an ethylacetate fraction or a methanol fraction of an artemisinus having high skin whitening activity and a method for producing the same.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a schematic view showing a process for producing the extract of the present invention or its fractions. FIG.
FIG. 2 is a graph showing the NO inhibiting activity of the extract of Artemisia princeps of the present invention.
FIG. 3 is a graph showing the DPPH radical scavenging activity of the extract of Artemisia princeps of the present invention.
FIG. 4 is a graph illustrating cytotoxicity of the extract of Artemisia princeps of the present invention.
FIG. 5 is a photograph showing the activity of suppressing intracellular melanin formation of the extract of Artemisia princeps of the present invention.
FIG. 6 is a graph showing the results of measuring intracellular melanin formation inhibitory activity of the extract of Artemisia princeps of the present invention.
FIG. 7 is a graph showing the results of measuring intracellular tyrosinase inhibitory activity of the extract of Artemisia princeps of the present invention.
FIG. 8 is a photograph and a graph showing the results of measurement of melanin production inhibitory activity of the extract of Artemisia japonica extract (a), ethyl acetate fraction (b) and water fraction (c) of the present invention.
FIG. 9 is a photograph and a graph showing the results of measuring the melanin production inhibitory activity of the methanol fraction and the hexane fraction of the present invention.
FIG. 10 is a photograph showing the results of confirming distribution of an active ingredient using the TLC of the individual extract of Artemisia princeps or extract of the present invention.
(A) Staining solution: Vanillin / H2SO4;
(B)
(C)
E: ethyl acetate fraction;
H: water fractions;
M: methanol fraction;
He: hexane fraction; And
Phosphorus: Artemisia extract (ethanol extract).
FIG. 11 is a photograph of melanin production inhibitory activity of each of the detailed fraction fractions (Fr. 1 to Fr. 7) of the present invention.
Hereinafter, the present invention will be described in detail.
The present invention provides a composition having an anti-inflammatory, antioxidant or skin whitening activity containing Artemisia capillaris extract or a fraction thereof as an active ingredient, and a composition for treating the same.
Artemisia capillaris (AC), a member of the genus Chrysanthemum mugwort, is known as an artemisia capillaris (AC), and its young stem and leaves are known to be indigenous to each other in Korea, and there are known dandruff, asthma suppression, Scoparone, Chlorogenic acid, Capillin, etc. are known as the components (Lee, Seong-hyun, pp. 1016-1017, 1998). A perennial herb belonging to Asteraceae Mugwort is several species as follows. Even if they belong to the same genus, they exhibit different effects due to differences in their characteristics, contained components and active substances.
The composition according to the present invention may be contained in any amount within a range that the extract of Artemisia princeps or its fraction is not toxic to the human body, and may be contained in an amount of 0.001 to 99.99% by weight based on the total weight of the composition.
The extract or its fractions inhibit NO production, eliminate active oxygen species, inhibit tyrosinase activity and melanin production, and are mediated by free radicals, ultraviolet irradiation, and inflammation during body metabolism It protects cell membranes by destroying the free radicals that are already damaged, and it has the effect of regenerating already damaged cells by active metabolism and proliferating cells.
Accordingly, the anti-inflammatory, antioxidant and skin whitening compositions containing the extract of Artemisia princeps or extract thereof according to the present invention as an active ingredient are effective for eliminating skin whitening effect, whitening effect and prevention and treatment of inflammatory reaction and eliminating free radicals, To prevent aging and maintain a clear and healthy skin.
In a specific embodiment of the composition according to the present invention, the composition may be used as a cosmetic composition. Forms such as emulsions, lotions, creams (water-in-oil type, water-in-water type, multiphase), solutions, suspensions (anhydrous and aqueous), anhydrous compounds (oil and glycol), gels, masks, packs or powders Oils, surfactants, fatty acids, silicone oils, wetting agents, moisturizers, viscosifying agents, emulsifiers, stabilizers, sunscreen agents, and the like, which can be suitably selected and used by those skilled in the art in cosmetic formulations , A coloring agent, a perfume, and the like.
In another specific embodiment of the composition according to the present invention, the composition may be used as a soap composition. Emulsifying agent, water softening agent, etc. as an additive to a soap base such as palm oil, palm oil, soybean oil, pharmacopoeial, olive oil and palm kernel oil, or animal fats such as tallow, lard, have. As the above-mentioned skin moisturizing agent, glycerin, erythritol, polyethylene glycol, propylene glycol, butylene glycol, pentylene glycol, hexyl glycol, isopropyl myristate, silicone derivatives, aloe vera, sorbitol, Wax fatty alcohols, hydrocarbons, natural plant extracts and the like can be used. As the water softening agent, tetrasodium edetate and the like can be used. The additive may further include an antimicrobial agent, a dispersant, a foam inhibitor, a solvent, a scouring inhibitor, a corrosion inhibitor, a perfume, a dye, a sequestering agent, an antioxidant, an antiseptic and the like.
In another specific embodiment of the composition according to the present invention, the composition can be used as a pharmaceutical composition. Specifically, it is a skin irritant caused by acne, atopy, psoriasis, dermatitis and the like caused by inflammation reaction, skin aging caused by increase of active oxygen, wrinkles, and stain, freckles, blotch, It can be used as a pharmaceutical composition having a preventive or therapeutic effect on a skin pigmentation disease such as a pigment, a pigment, a drug-induced pigmentation, and an inflammation-induced pigmentation. The pharmaceutical composition can be administered at various times during clinical administration, including oral, transdermal, subcutaneous, intravenous, or muscular, and can be applied as an external preparation for skin. In addition, formulations can be prepared in various formulations. In the case of formulation, formulations can be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents and surfactants that are usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, and such solid preparations may contain at least one excipient such as starch, calcium carbonate, sucrose, lactose and gelatin, . Examples of liquid preparations for oral administration include suspensions, solutions, emulsions and syrups. In addition to water and liquid paraffin which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, fragrances and preservatives . Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Witepsol, macrogol, tween 61, cacao paper, laurin, glycerol and gelatin may be used as a base for suppositories.
The composition of the present invention may be administered orally or parenterally in accordance with the intended method, and may be administered orally, parenterally or intraperitoneally, rectally, subcutaneously, intravenously, intramuscularly, . The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity.
The dosage of the composition of the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease, , Preferably 0.001 to 10 mg / kg, and may be administered 1 to 6 times a day.
The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers.
The health food of the present invention can be used as it is, or can be used in combination with other food or food ingredients, and can be suitably used according to a conventional method.
There is no particular limitation on the kind of the health food. Examples of the foods to which the mugwort extract or the fractions thereof can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen and other noodles, gums, ice cream, Tea, a drink, an alcoholic beverage, and a vitamin complex, all of which include health foods in a conventional sense.
The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. Such natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol and erythritol. Examples of sweeteners include natural sweeteners such as tau martin and stevia extract, synthetic sweeteners such as saccharin and aspartame, and the like. The ratio of the natural carbohydrate is generally about 0.01 to 0.04 g, preferably about 0.02 to 0.03 g per 100 g of the composition of the present invention.
In addition to the above, the health food of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
The present invention provides a method for producing Artemisia sp. Extract comprising extracting and fractionating Artemisia sp. Extract with an organic solvent.
The extract of Artemisia princeps or extract thereof according to the present invention is preferably produced by a method comprising the following steps, but is not limited thereto.
1) extracting Artemisia capillaris extract with an extraction solvent;
2) filtering the extract of step 1);
3) concentrating the filtered extract of step 2) under reduced pressure and then drying to prepare an extract of Artemisia princeps; And
4) Extraction of Artemisia sp. Extract of step 3) with an organic solvent to produce Artemisia sp. Fractions.
In this method, Artemisia Capillaris of step 1) can be used without limitation, such as cultivated or commercially available. It is most preferable that all organs such as leaves, flowers, roots, stems, and seeds are available, but it is not limited thereto.
In the above method, the extraction solvent of step 1) is preferably water, an alcohol or a mixture thereof. As the alcohol, C 1 to C 2 lower alcohol is preferably used, and as the lower alcohol, ethanol or methanol is preferably used. As the extraction method, it is preferable to use shaking extraction, Soxhlet extraction or reflux extraction, but it is not limited thereto. The extraction solvent is preferably added 1 to 5 times, more preferably 1 to 2 times, more preferably 1.5 times, more preferably 1 to 5 times. The extraction temperature is preferably 20 占 폚 to 100 占 폚, more preferably 20 占 폚 to 40 占 폚, and most preferably room temperature, but is not limited thereto. Further, the extraction time is preferably 10 to 48 hours, more preferably 12 to 36 hours, but is not limited thereto. The number of times of extraction is preferably 1 to 5 times, more preferably 1 to 2 times, more preferably 1 time, but is not limited thereto.
In the above method, it is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator in order to reduce the pressure in step 3), but the concentration is not limited thereto, and the concentration may be about 2 to 10 Brix as measured by a sugar content meter More preferably 3 to 6 bricks, but it is not limited thereto. The drying is preferably performed under reduced pressure, vacuum drying, boiling, spray drying or freeze drying, but not always limited thereto.
In the above method, the organic solvent in step 4) may be ethyl acetate, methanol, hexane, or a mixed solution thereof, preferably a mixed solution of water and ethyl acetate, a mixed solution of methanol and hexane, or a mixed solution of ethyl acetate and hexane But is not limited thereto.
The method for producing the fragrance fraction of step 4) may include extracting the extract of Artemisia princeps, using a mixed solution of water and ethyl acetate as a solvent, thereby obtaining the ethyl acetate fraction of the present invention.
At this time, the concentration of ethyl acetate in the mixed solution of water and ethyl acetate is preferably 40 to 70% by volume, more preferably 50 to 60%, most preferably 50%, but is not limited thereto.
The method for producing the fragrance fraction of step (4) may further include extracting the ethyl acetate fraction of the present invention using a mixed solvent of methanol and hexane as a solvent, thereby obtaining the methanol fraction of the present invention .
At this time, the concentration of methanol in the mixed solution of methanol and hexane is preferably 70 to 95% by volume, more preferably 80 to 90%, most preferably 90% It is possible.
The method for preparing the fragrant fraction of step 4) may include separating the methanol fraction of the present invention using a mixed solvent of ethyl acetate and hexane as a solvent, Fr.7) can be obtained.
At this time, the concentration of ethyl acetate in the mixed solution of ethyl acetate and hexane is preferably 10 to 70%, more preferably 20 to 50% or 55 to 70%, more preferably 20 to 50%, or 55 to 66% Most preferably, but not limited thereto.
The separation may be carried out using a normal silica gel (silicagel) or a reversed phase ODS (octadecylsilyl silica gel), but any method capable of gradient by concentration can be used.
The extraction temperature is preferably 20 to 100 ° C, more preferably 20 to 40 ° C, most preferably room temperature, but is not limited thereto. Further, the extraction time is preferably 10 to 48 hours, more preferably 12 to 36 hours, but is not limited thereto.
The fraction may be obtained by repeating the fractionation process from the extract of Artemisia capillaris 1 to 5 times, preferably 3 times, followed by fractionation and concentration under reduced pressure, but it is not limited thereto.
When the extract of Artemisia princeps or its fractions is prepared by the method of the present invention as described above, the active ingredient is prevented from being dispersed and a larger amount of the active fraction can be obtained. Thus, the antiseptic, antioxidant, It is possible to effectively obtain an extract or fraction which can be expressed.
Specifically, when the extract of Artemisia officinalis is extracted with a mixture of water and ethyl acetate, the water layer contains water-soluble components and the ethyl acetate layer contains a fat-soluble component. Means that the components are mostly lipophilic components. In addition, when only the ethyl acetate layer is separated and extracted with a mixed solution of methanol and hexane, hexane will contain lipid components, and the methanol layer will contain components with slightly higher polarity such as flavonoid and lignan, Means that the component exhibiting activity is a component having a somewhat higher polarity among fat-soluble components.
On the contrary, when a conventional solvent fractionation method is used, the active ingredients are dispersed in various solvents depending on the polarity, so that when the active ingredients are mostly polarized as in the present invention, a large amount of active ingredients It will be disadvantageous to obtain.
Accordingly, the production method of the present invention is an effective method for easily obtaining a larger amount of active ingredient by overcoming the limitations of the existing methods in the separation of active ingredients using Artemisia japonica.
Various formulation examples and formulation examples including the extract according to the present invention are described below, but the present invention is not intended to be limited but is to be specifically described.
Preparation Example 1. Preparation of tablets
Examples of the extract of Artemisia princeps or its fractions ... 100 mg
Starch ................................................. ...... 50 mg
Lactose ................................................. ...... 50 mg
Magnesium stearate ............................. 5mg
The above components were mixed and tablets were prepared by a wet granulation method or a dry granulation method according to a conventional method for producing tablets.
Formulation Example 2. Preparation of capsules
The extract of Artemisia princeps or its fractions in the examples ........ 0 mg
Starch ................................................. ... 50mg
Lactose ................................................. ... 50mg
Talc ................................................. ... 1mg
Magnesium stearate ............................. 5mg
The above components were mixed and capsules were prepared according to the conventional preparation method of capsules.
Formulation Example 3. Preparation of a liquid preparation
The extract of Artemisia princeps or its fractions of the examples ... 500 mg
Isolation Party ................................................ ..10g
saccharose................................................. ..... 10g
Lemon flavor ................................................ ... Appropriate amount
Purified water was added to the whole .............................. 50 ml
The above components were mixed according to a conventional method for preparing a liquid preparation, filled in a brown bottle, and sterilized to prepare a liquid preparation.
Formulation Example 4. Preparation of injection
The extract of Artemisia princeps or fraction thereof of the example ... 50 mg
Sodium Metabisulfite ........................... 2.6mg
Methylparaben ...................................... 0.5 mg
Propylparaben .................................... 0.1 mg
Sterilized distilled water for injection ................................ Appropriate amount
The above ingredients were mixed and adjusted to 2 ml in a conventional manner, filled in an ampoule and sterilized to prepare an injection.
Formulation Example 5. Preparation of beverage
Artemisia extract or its fractions of the examples: 100 mg
Vitamin B2 ................................................ 5 mg
Vitamin B6 ................................................ 5 mg
Vitamin C ................................................ ... 80 mg
Dietary fiber .............................................. 1000㎎
Liquid fructose ............................................ 10,000㎎
Emulsifier ................................................ 100 Mg
Lemon flavor ................................................ .
Purified water................................................. Proper amount
The above components were mixed to make a volume of 50 ml, the mixture was passed through a 3-μm filter, and the resulting filtered mixture was first sterilized at 90 to 93 ° C for 20 seconds, filled in a 50 ml bottle, Followed by secondary sterilization for 20 minutes to prepare a beverage product.
Formulation Example 1. Flexible lotion (skin lotion)
Artemisia sp. Extract or fractions thereof of the embodiment: 2.0
Glycerin ............................... 3.5
Oleyl alcohol ...................... 1.5
Ethanol ............................ 5.5
Carboxyl vinyl polymer 1.0
Butylene glycol .................... 2.0
Propylene glycol .................. 2.0
Preservatives, fragrances .....................
Purified water ...........................
Total ............................... 100
Flexible lotion was prepared according to the above composition in a conventional manner (unit weight%).
Formulation Example 2. Nourishing lotion (milk lotion)
Artemisia sp. Extract or fraction thereof of the examples
glycerin................................................. .3.0
Butylene glycol ...............................................
Propylene glycol ........................................ 3.0
Carboxyvinyl polymer .................................. 0.1
Wax ................................................. 4.0 ... 4.0
Caprylic / Capriculiglyceride ........... 5.0
Squalane ........................................ 5.0
Sorbitac esquioleate ........................... 1.5
Cetearyl Alcohol ................................. 1.0
Triethanolamine ................................... 0.2
Preservatives, fragrances ....................................
Purified water ........................................... Remainder
Total: 100
Nutrition lotion was prepared according to the above composition in a conventional manner (unit weight%).
Formulation Example 3. Nourishing cream
Artemisia sp. Extract or fractions thereof in the examples ...... 2.0
Glycerin ......................................... 3.5
Butylene glycol ....................................... 3.0
Liquid paraffin ....................................... 7.0
Beta Glucan ....................................... 7.0
Carbomer ........................................... 0.1
Caprylic / capric wriglyceride ...
Squalane ......................................... 5.0
Cetearyl Glucoside ........................... 1.5
Sorbitan stearate ............................ 0.4
Triethanolamine ................................... 0.1
Preservative, fragrance ....................................
Purified water .......................................... Remaining amount
Total ..................................... 100
Nutritive creams were prepared according to the above composition in a conventional manner (unit weight%).
Formulation Example 4. Pack
Artemisia sp. Extract or fractions thereof in the examples ........ 2.0
Glycerin ..................................... 4.0
Polyvinyl alcohol ........................... 15.0
Hyaluronic Acid Extract 5.0
Beta Glucan ................................. 7.0
Allantoin ....................................... 0.1
Nonyl phenyl ether ......................... 0.4
Preservative, fragrance ..............................
Purified water ......................................... Remaining amount
system................................................. ... 100
A pack was prepared according to the above composition in a conventional manner (unit weight%).
Formulation Example 5. Pharmaceutical preparation for local administration (patch)
Artemisia sp. Extract or fractions thereof in the examples 2.0
Beta-1,3-glucan ................................... 3.0
Diethylamine ............................................... 0.7
Sodium Sulfate ................................... 0.1
Polyoxyethylene lauryl ether (E.O. = 9) 1.0
Polyhydroxyethylene cetyl stearyl ether (Cetomacrogol 1000) 1.0
Viscous paraffin oil
Caprylic acid ester / capric acid ester (Cetiol LC) 2.5
Polyethylene glycol 400 .................................... 3.0
Polyacrylic acid (Carbopol 934P) ..................... 1.0
Purified water................................................. ........ Remainder
system................................................. ......... 100
According to the above composition, a medicament for topical administration was prepared by a conventional method (unit% by weight).
Formulation Example 6. Soap
Examples of the extract of Artemisia princeps or its
maintain................................................. ....... Appropriate amount
Sodium hydroxide ......................................... Appropriate amount
Sodium chloride ............................................. Appropriate amount
Spices................................................. .......handful
system................................................. ............. 100
A soap was prepared according to the above composition in a conventional manner (unit weight%).
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
Example 1. Preparation of Artemisia cinerea extract
Artemisia Capillaris ; AC; After 1 ~ 2 times of washing with distilled water and drying for 1 ~ 2 days at 20 ~ 60 ℃, 1,500 ml of alcohol, methanol or distilled water was added to 1,000 g of dried eggplant. And extracted at room temperature for 12 to 36 hours. Thereafter, the mixture was naturally filtered using a filter paper having a pore size of 5 쨉 m or less. The filtrate was concentrated by using a vacuum concentrator to a Brix of about 3 to 6 as measured by a sugar content meter, lyophilized, And homogenized to obtain 96.7 g of Artemisia sp.
Example 2. Preparation of fractionated organic solvent
2000 ml of ethyl acetate mixed solution (1000 ml of ethyl acetate, 1000 ml of water) was added to 96.7 g of the extract of Artemisia japonica extract (ethanol extract) of the present invention prepared through the alcohol (ethanol) in Example 1 at room temperature for 12 to 36 hours The ethyl acetate fraction and the water fraction were separated and filtered to prepare the ethyl acetate fraction and water fraction of the present invention, respectively.
The obtained ethyl acetate fraction (52.2 g) was further suspended in 1,400 ml of 90% methanol mixed solution (700 ml of 90% methanol, 700 ml of hexane) and extracted at room temperature for 12 to 36 hours. The residue was divided into a 90% methanol layer and a hexane layer The fractions were respectively separated / filtered to produce the methanol fraction and hexane fraction of the present invention.
Example 3. Preparation of fractionated fractions (Fr. 1 to Fr. 7) of organic solvent fraction
In order to obtain a sub-fraction exhibiting activity among the methanol fractions prepared in Example 2, 5 g of a 90% methanol fraction was used as a solvent, and a YMC-DispoPack AT SIL-25 column was used as a solvent containing ethyl acetate and hexane as a solvent. MPLC (LC-Forte / R, YMC) was performed. Starting with a solvent (20% ethyl acetate solution) with a ratio of ethyl acetate and hexane of 20:80 and gradually increasing the amount of ethyl acetate in the solvent until the concentration of ethyl acetate reaches 100% The solvent was flowed at a flow rate of 30 ml / min for 60 minutes. At this time, three wavelengths of 254 nm, 285 nm, and 356 nm were detected as the UV wavelength, and each fraction was fractionated based on the eluted peak to obtain a total of 7 fractions. This is named Fr.1 to Fr.7, and the time and solvent concentration of each fraction are shown in the table below.
The fractions isolated in each step were concentrated with a vacuum concentrator, lyophilized and homogenized with a mixer in the absence of moisture. The process of obtaining the extract of the present invention and its fractions is shown in FIG.
Experimental Example 1. Measurement of Anti-inflammatory Activity of Artemisia capillaris Extract
Induction of nitric oxide by induction of inflammatory reaction was measured by greiss reagent after stabilization of nitrite to nitrate. The inhibitory activity of nitric oxide (NO), an indicator of cellular inflammation, was determined by measuring the amount of nitrate produced during LPS - induced inflammation. Specifically, RAW264.7 cells were cultured in 96-well plates at a cell density of 5
As a result, LPS was a control group that induced inflammation reaction. Normal cells were not treated with LPS, and thus, NO inhibitory effect was not obtained. In addition, (See FIG. 2). From these results, it was found that the extract of Artemisia princeps of the present invention exhibits anti-inflammatory activity.
Experimental Example 2. Antioxidant activity measurement of Artemisia sp.
The antioxidative activity of free radical scavenging ability was measured by confirming the ability of reducing or canceling the free radical DPPH, that is, the oxidation inhibiting activity. DPPH was used as a measure of antioxidant activity because it was decolored and reduced by a sample with a relatively stable free radical having a deep purple color. L-ascorbic acid was used as a positive control and DPPH (1,1-diphenyl-2-picryl hydrazyl) method was used for comparison. 200 μl of 0.2 mM DPPH ethanol solution was successively diluted 2-fold with the extract of Artemisia japonica extract, reacted at room temperature for 30 minutes, and the absorbance at 517 nm was measured. The free radical scavenging activity was determined using the following equation, and the electron donating ability was expressed by the absorbance reduction rate of the sample solution addition group and no addition group.
Free radical scavenging ability (%) = (1 - absorbance of sample addition group / absorbance of no addition group)
As a result, DPPH radical scavenging activity was increased in a concentration dependent manner when the extract was treated by concentration, and about 84% of radical scavenging activity was observed at 100 ㎍ / ml treatment concentration. (See Fig. 3). Thus, it was found that the extract of Artemisia princeps of the present invention exhibits antioxidant activity.
Experimental Example 3. Measurement of whitening activity of Artemisia princeps
(1) preparation of cells
In the experiment for measuring whitening activity according to the present invention, melanoma-producing mouse-derived melanoma cells (B16F10 mouse melanoma cell) were used. The culture medium was 10% (v / v) FBS, 100 units / ml penicillin and 100 α-MEM containing streptomycin was used. The culture conditions were 5% CO 2 and 37 ° C.
(2) Cytotoxicity measurement
B16F10 cells were cultured in 96-well microplates at a concentration of 1 × 10 3 cells / well. After the cells were cultured for 48 hours, the supernatant was removed. MTT solution (100 μl) was treated at 36 ° C for 4 hours according to the measurement method of MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) and then the culture solution was removed and 50 μl of DMSO was treated And the absorbance was measured with an absorbance meter (ELISA) at 540 nm. The measured values were calculated by the following formula.
Cytotoxicity (%) = (1-absorbance of sample addition group / absorbance of no addition group)
As a result of comparing the survival rate of cells treated with B16F10 cells at various concentrations, the survival rate of B16F10 cells was not decreased, and thus it was confirmed that the B16F10 cells were not toxic to Melanoma cells (see FIG. 4).
(3) Measurement of intracellular melanin concentration
B16F10 cells were cultured in 6-well microplates at a concentration of 2 × 10 4 cells / well, and the samples were cultured for 48 hours, and the supernatant was removed. Cells were collected in tubes and melanin was eluted from the cells with NaOH and absorbance was measured at 405 nm.
When B16F10 cells were treated with the extract of Artemia japonica extract at different concentrations, melanocyte production was induced by stimulation of melanoma cells with α-MSH (Melanocyte Stimulating Hormone) Melanin production was inhibited. When the extract was administered at a concentration of 12.5 / / ml or more, the effect of inhibiting melanogenesis was excellent and the effect was excellent at a concentration of 12.5-100 / / ml, preferably 50-100 / / ml. In particular, when the concentration of Artemisia sp. Extract was 50 μg / ml, melanogenesis was suppressed to a degree similar to that of the control without α-MSH treatment (see FIG. 5). In addition, when melanin was extracted from cells and expressed as a concentration value, it was confirmed that melanogenesis was inhibited in a concentration-dependent manner (see FIG. 6).
(4) Measurement of intracellular tyrosinase activity
B16F10 cells were cultured in 6-well microplates at a concentration of 2 × 10 4 cells / well, and the samples were cultured for 48 hours, and the supernatant was removed. The cells dissolved in the buffer were reacted with L-DOPA (L-3,4, -dihydroxyphenylalanine) and absorbance was measured at 475 nm.
As a result of measuring the degree of inhibition of the enzymatic activity of the extract of Artemisia cinerea against the enzyme tyrosinase (tyrosinase), which is the most related to melanin formation in melanoma cells, melanoma cells were stimulated with α-MSH to induce melanogenesis , Tyrosinase activity was also increased (about 157% of tyrosinase activity was found in α-MSH treatment), and tyrosinase activity was inhibited in a concentration-dependent manner upon treatment with Artemisia sp. Extract (tyrosinase activity at a concentration of 50 μg / and about 107% when melanin without α-MSH was taken as 100%) (see FIG. 7). When the extract was administered at a concentration of 12.5 / / ml or more, the effect of inhibiting tyrosinase activity was excellent and the effect was excellent at a concentration of 12.5-100 / / ml, preferably 50-100 / / ml.
(5) Summary of results
As shown in Experimental Examples 1 to 3 of the present invention, the extract of Artemisia princeps of the present invention showed anti-inflammation, antioxidant or skin whitening activity, and the composition containing it as an active ingredient contained 12.5 to 100 ㎍ / ml, preferably 25 to 100 占 퐂 / ml, more preferably 50 to 100 占 퐂 / ml, exhibits excellent anti-inflammatory, antioxidative and whitening activity. It was confirmed that the same or similar effect was obtained at a concentration of 100 / / ml or more in the case of treatment with 100 / / ml, and the above-mentioned preferable concentration was in accordance with the concentration used in cell treatment in vitro , The present invention is not limited thereto.
Experimental Example 4. Measurement of whitening activity of organic solvent fraction
In order to confirm whether each of the organic solvent fraction (ethyl acetate fraction, water fraction, methanol fraction, and hexane fraction) of the present invention produced in Example 2 exhibited similar activity to the extract of Artemisia princeps, The intracellular melanin concentration was measured to confirm the whitening activity.
Specifically, the mouse-derived melanoma cells (B16F10 mouse melanoma cell) producing melanin were used for the measurement of whitening activity, and the culture medium was prepared by adding 10% (v / v) FBS, 100 units / ml penicillin and 100 unit / Α-MEM containing mitomycin was used. The culture conditions were 5% CO 2 and 37 ° C. For measurement of intracellular melanin concentration, B16F10 cells were cultured in a 6-well microplate at a concentration of 2 × 10 4 cells / well, and each sample (extract or fraction) was added to each concentration and cultured for 48 hours to remove the supernatant . Cells were collected in tubes and melanin was eluted from the cells with NaOH and absorbance was measured at 405 nm.
(1) Ethanol extract, (2) Ethyl acetate fraction, (4) Ethanol extract, (2) Ethyl acetate fraction, (3) Water fraction, ) Methanol fraction inhibited melanogenesis of cells in a concentration-dependent manner. In contrast, (3) water fraction and (5) hexane fraction did not inhibit the melanin production inhibitory activity (see FIGS. 8 and 9) .
The IC 50 value refers to the inhibitory concentration 50 (fifty), the inhibition concentration or the inhibition concentration. When the size of any reaction A is assumed to be 100%, the size of reaction A is reduced to 50% If possible, the concentration of B at that time is called the IC 50 of B for reaction A. If the IC 50 value is 1.4 μg / ml, it means that only 1.4 μg / ml is required to inhibit any reaction to 50%. As a result, the smaller the IC 50 value, the stronger the ability to inhibit the reaction. The IC 50 values of (1) ethanol extract, (2) ethyl acetate fraction and (4) methanol fraction showing whitening activity were compared and the results are shown in the table below.
As can be seen from the above results, the extract was prepared by extracting Artemisia japonica with ethanol and then sequentially extracted with a mixed solution of ethyl acetate and water and a mixed solution of 90% methanol and hexane. As a result, the ethyl acetate extract had the same weight 2.15 times, and the methanol fraction exhibited a high whitening activity (ability to inhibit melanin formation) of 3.74 times as much as the same weight.
As a result of TLC (Thin Layer Chromatography), it was confirmed that a substance expected to be an active ingredient exists only in a fraction exhibiting whitening activity upon irradiation with UV at a wavelength of 365 nm (see FIG. 10 (c)).
In conclusion, the ethyl acetate fraction and the methanol fraction thereof of the present invention show much higher whitening activity than the Artemisia sp. Extract, which can be expected because the active ingredient is concentrated.
Experimental Example 5. Measurement of whitening activity of fractionated fractions of Artemisia sp.
In order to confirm whether each of the fractions (Fr. 1 to Fr. 7) of the fragrant organic solvent fraction of the present invention produced in Example 3 exhibited similar activity to the extract of Artemisia princeps or its organic solvent fraction, The intracellular melanin concentration was measured in the same manner as in the method described in (3) to confirm whitening activity.
As a result, it was confirmed that whitening activity (inhibitory activity on melanin formation) was observed in
In conclusion, the extract of Artemisia japonica extract or its organic solvent fraction of the present invention exhibits excellent whitening activity. Particularly, the fractions obtained by sequentially treating the ethanol extract of Artemisia wisdomini with ethyl acetate and 90% methanol are mixed with 20% to 67% of ethyl It was found that the supernatant fractions obtained by further separation using acetate as a solvent showed the best activity. In particular, it was confirmed that the activity of inhibiting melanin formation was very high in Fr.1 to Fr3 and Fr.5 in which the concentration of ethyl acetate was 20 to 50% or 55 to 66%.
In addition, when compared with 500 ug arbutin used as a positive control, it was confirmed that melanin was hardly produced even when the fraction of the present invention was treated with 30 ug of 17-fold lower concentration. Thus, the fraction according to the present invention has a low concentration And thus it can be used effectively as an active ingredient of various compositions such as cosmetics, soaps, medicines or foods.
Having described specific portions of the present invention in detail, it will be apparent to those skilled in the art that this specific description is only a preferred embodiment and that the scope of the present invention is not limited thereby. It will be obvious. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (22)
1) extracting Artemisia capillaris with a solvent selected from water, methanol, ethanol or a mixed solvent thereof;
2) extracting the above extract with a solvent of water and ethyl acetate having a concentration of ethyl acetate of 40 to 70% to obtain an ethyl acetate fraction;
3) extracting the ethylacetate fraction with a solvent mixture of methanol and hexane having a methanol concentration of 70 to 95% to obtain a methanol fraction; And
4) The methanol fraction is separated using a mixed solvent of ethyl acetate and hexane as a solvent to obtain a fraction having a concentration of ethyl acetate in the solvent of 10 to 70%.
Wherein the mixed solution of water and ethyl acetate in step 2) has a concentration of ethyl acetate of 50 to 60%.
Wherein the mixed solution of water and ethyl acetate in step 2) has a concentration of ethyl acetate of 50%.
The mixture of methanol and hexane in step 3) has a methanol concentration of 80 to 90%.
Wherein the methanol and hexane mixed solution of step 3) has a methanol concentration of 90%.
Wherein the composition is a cosmetic composition.
(2) extracting the dried material with water, a C1-C2 alcohol, or a mixed solvent thereof;
(3) Extracting the extract obtained in the step (2) with a mixed solvent of ethyl acetate and water having a concentration of ethyl acetate of 40 to 70% as a solvent;
(4) extracting a mixed solution of methanol and hexane having a methanol concentration of 70 to 95% with a solvent in the extract obtained in the step (3);
(5) A method for producing an extract of Artemisia sp., Wherein the extract obtained in step (4) is obtained by fractionating a mixture of ethyl acetate and hexane with a solvent and obtaining a fraction having a concentration of ethyl acetate in the solvent of 10 to 70% Gt;
Wherein the separation of step (5) is carried out using a normal silica gel (silicagel) or reverse phase ODS (octadecylsilyl silica gel).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20140080630 | 2014-06-30 | ||
| KR1020140080630 | 2014-06-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160008100A KR20160008100A (en) | 2016-01-21 |
| KR101835739B1 true KR101835739B1 (en) | 2018-03-08 |
Family
ID=55308587
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150086839A KR101835739B1 (en) | 2014-06-30 | 2015-06-18 | Composition comprising extracts or fractions of Artemisia capillaris as an effective ingredient |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101835739B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102011837B1 (en) * | 2018-10-10 | 2019-10-21 | 주식회사 네오캠코리아 | Cosmetic composition comprising extract of Artemisia capillaris using heat-tinc extract method and low-temperature ripening |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018084671A1 (en) * | 2016-11-04 | 2018-05-11 | 동신대학교산학협력단 | Composition for preventing or treating pigmentation disorders |
| CN109952108A (en) * | 2016-11-15 | 2019-06-28 | 韩国科学技术研究院 | Including Artemisia annua extract as effective component for improving the composition and preparation method thereof of skin disease |
| KR20180063388A (en) | 2016-11-17 | 2018-06-12 | 인제대학교 산학협력단 | Compositions for Preventing or Treating Fulminant Hepatic Failure Comprising Water Soluble Extraction of Artemisia capillaris Thunb. |
| KR20180062682A (en) * | 2016-12-01 | 2018-06-11 | 인제대학교 산학협력단 | Aqueous extract of artemisia capillaris, and use and preparation method thereof |
| KR102196051B1 (en) * | 2019-01-25 | 2020-12-29 | (주)월드코스텍 | Skin functional composition containing fermented artemisia capillaris |
| KR102192004B1 (en) * | 2019-06-24 | 2020-12-16 | 김영지 | Shampoo composition for preventing hair loss and improving state of hair |
| KR102400179B1 (en) * | 2020-08-31 | 2022-05-25 | 주식회사에이치엔비랩스 | Cosmetic composition antimicroboal, antioxidation, whitening or anti-inflammation comprising artemisia capillaris thunberg and olive extract |
-
2015
- 2015-06-18 KR KR1020150086839A patent/KR101835739B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| J. Korean Ind. Eng. Chem., 제16권, 제3호, 제348-353면(2005.06.)* |
| J. Vet. Clin., 제24권, 제2호 제130-136면(2007.06.)* |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102011837B1 (en) * | 2018-10-10 | 2019-10-21 | 주식회사 네오캠코리아 | Cosmetic composition comprising extract of Artemisia capillaris using heat-tinc extract method and low-temperature ripening |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160008100A (en) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101835739B1 (en) | Composition comprising extracts or fractions of Artemisia capillaris as an effective ingredient | |
| US20230075384A1 (en) | Composition containing plant extracts | |
| WO2020060060A1 (en) | Cosmetic composition comprising centella asiatica adventitious root extract as effective ingredient for skin whitening and wrinkle reduction | |
| KR102472974B1 (en) | Composition for improving skin | |
| KR102573375B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR102543552B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20110054747A (en) | A composition for skin wrinkle improvement comprising extracts or fractions of eremochloa ophiuroides as an active ingredient | |
| KR102011639B1 (en) | Composition for anti-oxidant, skin whitening and anti-wrinkle effect comprising Glehnia Radix leaf extract as effective component | |
| KR101848252B1 (en) | A composition comprising the Leukodin isolated from the extract of Artemisia Capillaris for skin whitening | |
| KR101668357B1 (en) | Composition for improving skin conditions and method for improving skin conditions using the same | |
| KR102689774B1 (en) | Composition for improving skin | |
| KR102264006B1 (en) | Composition for inhibiting production of melanin and promoting decomposition of melanin | |
| KR101931611B1 (en) | Composition for antioxidant, and anti-inflammation effect comprising Cirtus extract and Hylotelephium erythrostictum extract | |
| KR102548897B1 (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR20180060611A (en) | Composition for improving skin | |
| KR102283012B1 (en) | Whitening composition comprising an extract of Elaeagnus macrophylla or a fraction thereof as an active ingredient | |
| KR102577528B1 (en) | Composition for improving skin | |
| KR20140089305A (en) | Composition for improving skin whitening or skin wrinkle comprising extracts of Quercus salicina Blume | |
| KR102244585B1 (en) | Complex cosmetic composition for improving skin-aging | |
| KR102183896B1 (en) | Composition for improving skin | |
| KR101419587B1 (en) | Composition for Promoting Regeneration of Skin Comprising Ginseng Oil as Active Ingredient | |
| KR20170137560A (en) | Composition for improving skin condition comprising herb extracts mixture | |
| KR101909225B1 (en) | A composition comprising the Isoscopoletin isolated from the extract of Artemisia Capillaris for anti-wrinkle | |
| KR20100042086A (en) | Composition for whitening containing extract of cortex cinnamomi cassiae | |
| KR101720712B1 (en) | Composition for improving skin comprising levistilide A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| N231 | Notification of change of applicant | ||
| E701 | Decision to grant or registration of patent right |